Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans

Pancreatic ductal adenocarcinoma (PDAC) is currently the third leading cause of cancer mortality and the incidence is projected to increase by 2030. Despite recent advances in its treatment, African Americans have a 50-60% higher incidence and 30% higher mortality rate when compared to European Amer...

Descripción completa

Detalles Bibliográficos
Autores principales: Telisnor, Guettchina, DeRemer, David L., Frimpong, Esther, Agyare, Edward, Allen, John, Ricks-Santi, Luisel, Han, Bo, George, Thomas, Rogers, Sherise C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10639003/
https://www.ncbi.nlm.nih.gov/pubmed/36801148
http://dx.doi.org/10.1016/j.jnma.2023.01.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10639003/
https://www.ncbi.nlm.nih.gov/pubmed/36801148
http://dx.doi.org/10.1016/j.jnma.2023.01.008

Ejemplares similares